Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.

nork Webster, L. K., Cosson, E. J., Stokes, K. H., Millward, M. J.
Argitaratua 1996

Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.

nork Millward, M. J., Cantwell, B. M., Dowsett, M., Carmichael, J., Harris, A. L.
Argitaratua 1991

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.

nork Millward, M. J., Cantwell, B. M., Munro, N. C., Robinson, A., Corris, P. A., Harris, A. L.
Argitaratua 1993

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma

nork Warburton, L., Meniawy, T. M., Calapre, L., Pereira, M., McEvoy, A., Ziman, M., Gray, E. S., Millward, M.
Argitaratua izan da Sci Rep (2020)

A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer.

nork Ball, D., Smith, J., Bishop, J., Olver, I., Davis, S., O'Brien, P., Bernshaw, D., Ryan, G., Millward, M.
Argitaratua 1997

A phase II trial of paclitaxel and epirubicin in advanced breast cancer

nork Rischin, D, Smith, J, Millward, M, Lewis, C, Boyer, M, Richardson, G, Toner, G, Gurney, H, McKendrick, J
Argitaratua 2000

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.

nork Lind, M. J., Cantwell, B. M., Millward, M. J., Robinson, A., Proctor, M., Simmons, D., Carmichael, J., Harris, A. L.
Argitaratua 1992

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours

nork Millward, M, Underhill, C, Lobb, S, McBurnie, J, Meech, S J, Gomez-Navarro, J, Marshall, M A, Huang, B, Mather, C B
Argitaratua 2013

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma

nork Creaney, J, Segal, A, Sterrett, G, Platten, M A, Baker, E, Murch, A R, Nowak, A K, Robinson, B W S, Millward, M J
Argitaratua 2008

The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.

nork Lind, M. J., Gumbrell, L., Cantwell, B. M., Millward, M. J., Simmonds, D., Proctor, M., Chapman, F., McCann, E., Middleton, I., Calvert, A. H.
Argitaratua 1995

Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression

nork Reid, A.L., Millward, M., Pearce, R., Lee, M., Frank, M.H., Ireland, A., Monshizadeh, L., Rai, T., Heenan, P., Medic, S., Kumarasinghe, P., Ziman1, M.
Argitaratua 2012

The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study

nork Millward, M J, House, C, Bowtell, D, Webster, L, Olver, I N, Gore, M, Copeman, M, Lynch, K, Yap, A, Wang, Y, Cohen, P S, Zalcberg, J
Argitaratua 2006

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

nork Bowyer, S, Prithviraj, P, Lorigan, P, Larkin, J, McArthur, G, Atkinson, V, Millward, M, Khou, M, Diem, S, Ramanujam, S, Kong, B, Liniker, E, Guminski, A, Parente, P, Andrews, M C, Parakh, S, Cebon, J, Long, G V, Carlino, M S, Klein, O
Argitaratua izan da Br J Cancer (2016)

RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers

nork Falchook, G.S., Long, G.V., Kurzrock, R., Kim, K.B., Arkenau, H.T., Brown, M.P., Hamid, O., Infante, J.R., Millward, M., Pavlick, A., O’Day, S.J., Blackman, S.C., Curtis, C.M., Lebowitz, P., Ma, B., Ouellet, D., Kefford, R.F.
Argitaratua 2012

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

nork Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M. A., Lane, S. R., Legos, J. J., Mookerjee, B., Grob, J.-J.
Argitaratua izan da Ann Oncol (2017)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

nork Long, G V, Flaherty, K T, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalá, M, Millward, M, Arance, A, Bondarenko, I, Haanen, J B A G, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, M A, Lane, S R, Legos, J J, Mookerjee, B, Grob, J -J
Argitaratua izan da Ann Oncol (2019)